The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

Release Date: February 2015

Number of Pages: 249

Number of Tables and Figures: 54

Synopsis: A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

For a sample of the report or any further inquiries please contact

Pricing: The report is available for the following price:

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:

The report has the following key findings:

  • Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
  • As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
  • In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
  • In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered:

The report covers the following topics:

  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation:

Market forecasts are provided for each of the following submarkets and their subcategories:

  • Brand Classification
    • Pure (Non-branded) Generics
    • Branded Generics
    • Super Generics
  • Therapeutic Area
    • Antibiotics
    • Cardiovascular & Hypertension
    • CNS (Central Nervous System)
    • Dermatology
    • Diabetes
    • Gastrointestinal
    • Hormonal Drugs
    • Oncology
    • Pain Relief
    • Respiratory
    • Rheumatology
    • Others
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:

The report provides answers to the following key questions:

  • How big is the generic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for generic cancer drugs?
  • How does regulation impact the adoption of generic drugs?
  • How will branded and super generics impact revenue prospects?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of biologics impact the market?
  • What are the future prospects of approved and non-approved biosimilar drugs?
  • What strategies should generic and innovator drug manufacturers adopt to remain competitive?

List of Companies Mentioned:

The following companies and organizations have been reviewed, discussed or mentioned in the report:

Abbott Laboratories


ACETO Corporation

Acino Holding



Adcock Ingram

Aesica Pharmaceuticals



Alexion Pharmaceuticals

Alfa Wasserman



AMA (African Medicines Regulatory Agency)


Amneal Pharmaceuticals

AMRI (Albany Molecular Research, Inc.)



Arch Pharmalabs

ASKA Pharmaceutical Company

Aspen Holdings

Astellas Pharma


Aurobindo Pharma

Auxilium Pharmaceuticals

Baxter BioScience

Baxter International

Bayer AG

BD (Becton, Dickinson and Company)


Berlin Chemie



Biogen Idec

Biogen Laboratorios

BMS (Bristol-Myers Squibb)

Boehringer Ingelheim

Boots UK

BPI (Breckenridge Pharmaceutical Inc.)

Breckenridge Pharmaceutical

Cadila Healthcare (Zydus Cadila)

Cadila Pharmaceuticals

CBER (Centre for Biologics Evaluation and Research)

CDER (Centre for Drug Evaluation and Research)

CDSCO (Central Drug Standards and Control Organization, India)

Cedarburg Pharmaceuticals

Celgene Corporation

Celltrion Group

CFDA (China Food and Drug Administration)

Chiesi Farmaceutici

Chugai Pharmaceutical Company


Claris Injectables

Claris Lifesciences

Claris Otsuka

Coherus BioSciences

Consort Medical


Cubist Pharmaceuticals

Cypress Pharmaceutical

Daiichi Sankyo

Daiichi Sankyo Espha

Dong-A Pharmaceutical

Dr. Reddy's Laboratories

Dusa Pharmaceuticals

EGA (European Generic Medicines Association)

Egis Pharmaceuticals

Eisai Company

Eli Lilly and Company

Elmed Eisai Company

EMA (European Medicines Agency)

Endo International

Endo Pharmaceuticals



Eurofarma Laboratorios

FDA (Food and Drug Administration)

Ferring Pharmaceuticals

Forest Laboratories

Fresenius Kabi

Fuji Pharma Company

Fujifilm Corporation

Fujifilm Holdings Corporation

Fujifilm Pharma Company



Gedeon Richter

Gedeon Richter PregLem


GGL (Glenmark Generics Limited)

Gilead Sciences

Glenmark Pharmaceuticals

Global Pharmaceuticals



Gruenenthal Group

GSK (GlaxoSmithKline)

Guangdong BeiKang Pharmaceutical Company

Hanmi Pharmaceutical Company

Health Canada

Hetero Drugs

Hikma Pharmaceuticals

Hi-Tech Pharmacal


Impax Laboratories

Impax Pharmaceuticals


Janssen Pharmaceutica

Jazz Pharmaceuticals

JHP Group Holdings

JHP Pharmaceuticals

Johnson & Johnson

JT (Japan Tobacco)

Kaken Pharmaceutical Company

Kaneka Corporation

Kowa Company

Kowa Health Care America

Kowa Pharmaceuticals America

Kowa Research Institute

Kremers Urban Pharmaceuticals

Krka (Krka, d. d.)

Kyowa Hakko Kirin Company

Kyowa Pharmaceutical Industry Company

Laboratorios Roemmers

Leo Pharma

Les Laboratoires Servier

Lil Therapeutics

Lundbeck (H. Lundbeck A/S)



Maruho Company

Matrix Laboratories


Medley Farma

Meiji Holdings

Meiji Seika Pharma Company

Menarini Group

Merck and Co.

Merck KGaA

Merck Serono

Merz Pharma

Ministry of Health, Labour and Welfare (Japan)

Mitsubishi Chemical Holdings Corporation

Mitsubishi Tanabe Pharma

Mitsui & Company

Mitsui Group

MN (Mustafa Nevzat) Pharma


Natco Pharma

Nichi-Iko Pharmaceutical Company

Nippon Kayaku

Nippon Shinyaku

Nipro Pharma Corporation

Novartis International

Novo Nordisk

OLIC (Thailand)

Ono Pharmaceutical Company

Orion Corporation

Osaka Synthetic Chemical Laboratories

Otsuka Holdings Company

Otsuka Pharmaceutical Company

Paladin Labs

Par Pharmaceutical Companies

Pensa Dose

Pensa Pharm

Perrigo Company


Pharma Dynamics


Pierre Fabre (Laboratoires Pierre Fabre)

Piramal Enterprises

Piramal Group

Pliva (Pliva d.d.)

Prasco Laboratories


Purdue Pharma

Qualitest and Vintage Pharmaceuticals

Ranbaxy Laboratories


Regeneron Pharmaceuticals

Rising Pharmaceuticals

Roche Holding (F. Hoffmann-La Roche)

Roxane Laboratories

Salix Pharmaceuticals

Samsung Bioepis

Samsung BioLogics

Samsung Group

Sandoz International


Sanofi-Aventis Nichi-Iko K.K.

Santen Pharmaceutical Company

Sawai Pharmaceutical Company

Seikagaku Corporation

Sequent Scientific

Servier Group

Shionogi & Company



Somar (Grupo Farmaceutico Somar)

STADA Arzneimittel

Strativa Pharmaceuticals

Strides Arcolab

Sumitomo Dainippon Pharma Company

Sun Pharmaceutical Industries

Supera Farma Laboratorios

Taisho Pharmaceutical Company

Taisho Pharmaceutical Holdings Company

Taisho Pharmaceutical Industries

Taiyo Pharmaceutical Industry Company

Takeda Pharmaceutical Company

Tanabe Seiyaku Hanbai Company

Taro Pharmaceutical Industries


Teijin Pharma

Teva Pharmaceutical Industries

Teva-Kowa Pharma Company

The Medicines Company

Torrent Group

Torrent Pharmaceuticals

Towa Pharmaceutical Company


United Therapeutics Corporation

Valeant Pharmaceuticals International

Ventana Medical Systems

Vertex Pharmaceuticals


West-Ward Pharmaceuticals

WHO (World Health Organization)